PapersFlow Research Brief
Myasthenia Gravis and Thymoma
Research Guide
What is Myasthenia Gravis and Thymoma?
Myasthenia gravis and thymoma refers to the clinical association between myasthenia gravis, an autoimmune neuromuscular disorder characterized by autoantibodies targeting the neuromuscular junction, and thymoma, a thymic tumor often linked to this condition through thymic abnormalities.
Research on myasthenia gravis and thymoma encompasses 67,883 works, focusing on autoantibodies, thymectomy efficacy, and thymic tumor prognosis. Huub Oosterhuis (1997) in "Myasthenia Gravis" provides a foundational review of the disease's clinical features and subgroups. Akira Masaoka et al. (1981) in "Follow-up study of thymomas with special reference to their clinical stages" reported a five-year survival rate of 74.1% for 96 thymoma cases, rising to 88.9% with total resection.
Topic Hierarchy
Research Sub-Topics
Acetylcholine Receptor Antibodies in Myasthenia Gravis
This sub-topic examines the role of autoantibodies against acetylcholine receptors in the pathogenesis of myasthenia gravis, including their detection, prevalence, and correlation with disease severity. Researchers study diagnostic assays, epitope mapping, and therapeutic modulation of these antibodies.
MuSK Antibodies in Seronegative Myasthenia Gravis
This sub-topic focuses on muscle-specific kinase (MuSK) autoantibodies in patients lacking AChR antibodies, exploring their distinct clinical phenotypes and neuromuscular junction disruptions. Researchers investigate treatment responses and pathophysiological mechanisms unique to MuSK-MG.
Thymectomy Outcomes in Myasthenia Gravis
This sub-topic covers clinical trials and long-term studies on thymectomy efficacy in non-thymomatous and thymomatous myasthenia gravis, including remission rates and predictors of response. Researchers analyze surgical techniques, timing, and postoperative immunological changes.
Thymoma Classification and Prognosis
This sub-topic addresses histopathological classification systems like Masaoka-Koga and WHO schemas for thymic tumors associated with myasthenia gravis, alongside prognostic factors and survival analyses. Researchers study molecular markers and staging impacts on recurrence and paraneoplastic syndromes.
Epidemiology of Myasthenia Gravis and Thymoma
This sub-topic investigates incidence, prevalence, risk factors, and geographic variations in myasthenia gravis and its association with thymoma. Researchers analyze demographic trends, genetic predispositions, and environmental influences on disease clusters.
Why It Matters
Myasthenia gravis and thymoma research guides treatment decisions, particularly thymectomy, which improves outcomes in associated cases. In "Follow-up study of thymomas with special reference to their clinical stages," Masaoka et al. (1981) showed that total resection achieved an 88.9% five-year survival rate compared to 44.4% in non-radically treated thymoma patients, informing surgical standards. Antibody detection, as in Lindstrom et al. (1976) "Antibody to acetylcholine receptor in myasthenia gravis," identified acetylcholine receptor antibodies in 87% of 71 myasthenia gravis patients, enabling targeted immunotherapy. Gilhus and Verschuuren (2015) in "Myasthenia gravis: subgroup classification and therapeutic strategies" outline strategies for autoantibody-specific therapies, reducing reliance on broad immunosuppressants in neurology clinics.
Reading Guide
Where to Start
"Myasthenia Gravis" by Huub Oosterhuis (1997) provides a foundational overview of clinical features, subgroups, and thymoma associations, making it the ideal starting point for understanding core concepts before diving into specific studies.
Key Papers Explained
Oosterhuis (1997) "Myasthenia Gravis" establishes disease basics, which Lindstrom et al. (1976) "Antibody to acetylcholine receptor in myasthenia gravis" builds on by quantifying acetylcholine receptor antibodies in 87% of cases. Hoch et al. (2001) "Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies" extends this to MuSK-positive subgroups. Masaoka et al. (1981) "Follow-up study of thymomas with special reference to their clinical stages" connects thymoma staging to survival, while Gilhus and Verschuuren (2015) "Myasthenia gravis: subgroup classification and therapeutic strategies" synthesizes these for modern treatment.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Gilhus and Verschuuren (2015) "Myasthenia gravis: subgroup classification and therapeutic strategies" highlights ongoing refinements in autoantibody-based therapies. Masaoka staging from 1981 remains central to thymoma prognosis discussions. No recent preprints or news indicate stable frontiers in subgroup immunotherapy and surgical outcomes.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | A serum autoantibody marker of neuromyelitis optica: distincti... | 2004 | The Lancet | 3.2K | ✕ |
| 2 | Myasthenia Gravis | 1997 | — | 2.4K | ✕ |
| 3 | Follow-up study of thymomas with special reference to their cl... | 1981 | Cancer | 1.7K | ✕ |
| 4 | Localized mediastinal lymph-node hyperplasia resembling thymoma | 1956 | Cancer | 1.6K | ✓ |
| 5 | Myasthenia gravis | 2000 | Neurology | 1.6K | ✕ |
| 6 | Paresis Acquired in the Intensive Care Unit<SUBTITLE>A P... | 2002 | JAMA | 1.5K | ✕ |
| 7 | Muscle Biopsy: A Modern Approach | 1974 | Archives of Neurology | 1.4K | ✕ |
| 8 | Antibody to acetylcholine receptor in myasthenia gravis | 1976 | Neurology | 1.2K | ✓ |
| 9 | Auto-antibodies to the receptor tyrosine kinase MuSK in patien... | 2001 | Nature Medicine | 1.2K | ✕ |
| 10 | Myasthenia gravis: subgroup classification and therapeutic str... | 2015 | The Lancet Neurology | 1.2K | ✕ |
Frequently Asked Questions
What is the survival rate for thymoma patients?
In a follow-up of 96 thymoma cases, the five-year survival rate was 74.1% overall and 88.9% for the total resection group, per Masaoka et al. (1981) in "Follow-up study of thymomas with special reference to their clinical stages." The ten-year survival rate was 57.1%. Non-radically treated cases had a five-year survival of 44.4%.
How prevalent are acetylcholine receptor antibodies in myasthenia gravis?
Lindstrom et al. (1976) in "Antibody to acetylcholine receptor in myasthenia gravis" detected elevated acetylcholine receptor antibodies in 87% of sera from 71 myasthenia gravis patients. These antibodies were absent in 175 sera from individuals without myasthenia gravis, including those with other neurologic or autoimmune diseases. This marker distinguishes myasthenia gravis cases.
What defines clinical stages in thymoma?
Masaoka et al. (1981) in "Follow-up study of thymomas with special reference to their clinical stages" defined stages based on tumor encapsulation and invasion, correlating with survival outcomes in 96 cases. Stage I involved macroscopic encapsulation, while higher stages showed invasion. Staging predicted prognosis and guided resection decisions.
What are MuSK antibodies in myasthenia gravis?
Hoch et al. (2001) in "Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies" identified MuSK autoantibodies in patients lacking acetylcholine receptor antibodies. These target the muscle-specific kinase at the neuromuscular junction. This finding defines a key subgroup for targeted therapies.
How does thymectomy impact myasthenia gravis?
Thymectomy is a standard treatment for myasthenia gravis associated with thymoma, as explored in foundational works like Jaretzki et al. (2000) "Myasthenia gravis." It addresses thymic tumor sources of autoantibodies. Masaoka et al. (1981) linked radical resection to improved survival in thymoma cases.
What is the scope of myasthenia gravis subgroup research?
Gilhus and Verschuuren (2015) in "Myasthenia gravis: subgroup classification and therapeutic strategies" classify subgroups by autoantibodies like acetylcholine receptor and MuSK. This guides immunotherapy choices. The field includes 67,883 papers on clinical correlates and treatments.
Open Research Questions
- ? How do thymic tumors specifically drive autoantibody production in myasthenia gravis subgroups?
- ? What factors determine long-term prognosis beyond five years in resected thymomas?
- ? Which autoantibody profiles predict response to thymectomy in non-thymoma myasthenia gravis?
- ? How can clinical staging systems for thymoma be refined for better survival prediction?
- ? What role do MuSK antibodies play in neuromuscular junction pathology without acetylcholine receptor involvement?
Recent Trends
The field maintains 67,883 works with no specified five-year growth rate.
Gilhus and Verschuuren "Myasthenia gravis: subgroup classification and therapeutic strategies" represents the most recent top-cited paper, emphasizing autoantibody-driven therapies.
2015No preprints or news from the last 12 months signal steady progress without major shifts.
Research Myasthenia Gravis and Thymoma with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Myasthenia Gravis and Thymoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers